Bernard-Soulier syndrome (BSS) is one of a group of hereditary platelet disorders characterized by thrombocytopenia, giant platelets, and qualitative platelet defects resulting in bleeding tendency.  See the image below.
Signs and symptoms
Symptoms of BSS may include the following:
Gastrointestinal bleeding (occasional)
Physical findings may include the following:
Purpura and petechial rash
See Presentation for more detail.
The following diagnostic studies may be helpful:
Complete blood count (CBC), including peripheral smear (showing giant platelets and thrombocytopenia)
Bleeding time/platelet function analyzer-100 (PFA-100) test (both are usually prolonged)
Platelet aggregation studies (platelets do not aggregate in response to ristocetin even after adding normal plasma but do have normal aggregation in response to adenosine diphosphate, epinephrine, and collagen)
See Workup for more detail.
Care of patients with Bernard-Soulier syndrome (BSS) is generally supportive. In most cases, no medications are needed. Bleeding episodes may require nonspecific treatment, such as Desmopressin acetate (DDAVP) or antifibrinolytic agents. Treatment principles include the following:
In all cases, antiplatelet medications should be avoided
Antifibrinolytic agents may be useful for mucosal bleeding
Platelet transfusion is the only available therapy for surgery or potentially life-threatening hemorrhage
DDAVP shortens the bleeding time in some, but not all, BSS patients and may be useful for minor bleeding episodes
Recombinant activated factor VII may be considered
For patients with moderate-to-severe symptoms, some restriction of activity may be necessary
See Treatment and Medication for more detail.
Bernard-Soulier syndrome (BSS) was first described in 1948 as a congenital bleeding disorder characterized by thrombocytopenia and large platelets. The disorder was recognized to be familial and inherited in an autosomal recessive manner. In the 1970s, the molecular defect was shown to involve the absence of a platelet membrane glycoprotein (GPIb/IX/V) complex which is the receptor for von Willebrand factor (vWF).
BSS is one of a group of hereditary platelet disorders characterized by macrothrombocytopenia and a tendency toward bleeding. It is the second most common inherited platelet defect. Other disorders in the category of macrothrombocytopenia are the May-Hegglin anomaly and gray platelet syndrome.
Treatment is generally supportive. Patients should be educated about the disease and the need to avoid trauma and nonsteroidal anti-inflammatory drugs (NSAIDS). Emphasis should be placed on good dental hygiene.
Pathophysiology and Etiology
The underlying biochemical defect in BSS is the absence or decreased expression of the GPIb/IX/V complex on the surface of the platelets. [2, 3, 4, 5] This complex is the receptor for von Willebrand factor (vWF), and the result of decreased expression is deficient binding of vWF to the platelet membrane at sites of vascular injury, resulting in defective platelet adhesion. GPIb/IX/V complex is located in the platelet cytoskeleton and hence is also essential to the production of platelets from the megakaryocytes in the bone marrow (which explains the large size and decreased numbers of platelets in this syndrome).
Defective platelet adhesion is demonstrated by the lack of platelet aggregation in response to ristocetin, an antibiotic that normally causes platelets to aggregate. The end result is the lack of formation of the primary platelet plug, together with an increased bleeding tendency. The cause of the thrombocytopenia is not definitely known but is thought probably to be related to the absence of the GPIb/IX/V complex and its role in the production and shedding of platelets from the marrow megakaryocytes. 
BSS is inherited in an autosomal recessive fashion; thus, males and females are affected with equal frequency. (A rare variant with autosomal dominant inheritance has been described.) Heterozygotes have been thought to usually have no bleeding manifestations. However, a study by Bragadottir et al indicated that individuals who are heterozygous for BSS mutations have lower platelet counts, more mucocutaneous bleeding, and higher vWF levels than do controls without these mutations, although bleeding is much milder than in persons who are homozygous for BSS. 
Epidemiology and Prognosis
BSS is rare, with an estimated occurrence of less than 1 case per million population. Bleeding due to BSS may begin in infancy and may continue with varying severity throughout life, although it may somewhat diminish with age. Males and females are affected with equal frequency. To date, BSS has been described primarily in whites of European ancestry, as well as in the Japanese population; its prevalence in other ethnic groups is unknown.